Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Increased psychological symptom burden in patients with pancreatic cancer: A population-based cohort study: Increased psychological symptom burden in patients with pancreatic cancer

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Coronavirus Disease-19 (COVID-19) associated with severe acute pancreatitis: Case report on three family members

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The cost of endoscopic treatment for walled-off pancreatic necrosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. How do people with rheumatoid arthritis experience participation in a smoking cessation trial: a qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Acinar cystic transformation of the pancreas: Report of a case and a review of the literature

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND/OBJECTIVE: To investigate the psychological symptom burden in patients with pancreatic cancer.

METHODS: We used Danish population-based registries to identify 10,793 pancreatic cancer patients and 109,238 age and gender matched cancer-free comparison persons between the years 2000-2016. The cohorts were followed up to five years for first prescription for antidepressants, anxiolytics or hypnotics as proxies for the psychological symptom burden of depression, anxiety or insomnia. Cumulated incidence proportions were analysed using the pseudo-value approach and hazards were estimated with Cox regression models adjusted for potential confounders.

RESULTS: The highest HR for first antidepressant use was seen in the first six months after diagnosis (HR 8.73 (95% CI: 7.57; 10.06)). Within the first two years the overall estimated cumulated probability of 12.9% (95% CI: 12%; 13.8%) in pancreatic cancer patients, and 4.6% (95% CI: 4.5%; 4.8%) in comparisons, and 20.4% and 31.4% patients received first prescription of anxiolytics or hypnotics, respectively. We found no difference in HRs of first antidepressant by gender, year of diagnosis, cohabitation, education or comorbidity in the patient cohort, however younger age (<59 years) was associated with depression.

CONCLUSIONS: Pancreatic cancer patients are at risk for first antidepressant, anxiolytic and hypnotic use up to five years after diagnosis. Patients younger than 59 years, newly diagnosed with advanced pancreatic cancer, and not treated with surgery were more likely to have first antidepressant use. The study calls for interventions to reduce the psychological burden in advanced pancreatic cancer patients which may improve quality of life and survival.

Original languageEnglish
JournalPancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
Volume20
Issue number3
Pages (from-to)511-521
Number of pages11
ISSN1424-3903
DOIs
Publication statusPublished - Apr 2020

    Research areas

  • Anxiety, Cancer, Depression, Epidemiology, Insomnia

ID: 59211499